Myasthenia Gravis Treatment Market Share, Treatment Innovation and Future Growth Prospects

Myasthenia gravis treatment refers to medical therapies used to manage this chronic autoimmune neuromuscular disorder, which causes weakness in voluntary muscles.

According to Straits Research, the global myasthenia gravis treatment market size was valued at USD 2.32 billion in 2025 and is projected to grow from USD 2.55 billion in 2026 to USD 5.49 billion by 2034, registering a CAGR of 10.05% during the forecast period. North America held the largest regional share at 42.5% in 2025, while Asia Pacific is expected to record the fastest growth at a CAGR of 9.2%. Advances in targeted immunotherapies and wider access to specialist neurological care are expected to support market growth.

  • Market Size 2025: USD 2.32 billion

  • Market Size 2026: USD 2.55 billion

  • CAGR (Forecast Period): 10.05%

  • Forecast Year: 2034

  • Projected Market Size: USD 5.49 billion

  • Dominant Region: North America – 42.5% share in 2025

  • Fastest Growing Region: Asia Pacific – 9.2% CAGR

Market Overview

Myasthenia gravis is a chronic autoimmune disorder that disrupts communication between nerves and muscles, leading to weakness in voluntary muscles. Treatment aims to control symptoms, reduce abnormal immune activity, and improve daily function. Available approaches include medication, plasmapheresis, intravenous immunoglobulin, surgery, and other specialized therapies. The development of targeted biologic medicines has broadened treatment options for patients with generalized myasthenia gravis.

Growth Drivers

  • Greater Use of Targeted Immunotherapies: Targeted medicines that act on complement pathways or neonatal Fc receptors provide additional options for patients who need disease-specific treatment. Their clinical use supports demand for advanced therapies.

  • Improved Disease Awareness and Diagnosis: Greater awareness among clinicians and patients can support earlier diagnosis and more timely care. Improved diagnostic methods also help identify disease subtypes and guide treatment selection.

  • Need for Long-Term Symptom Control: Myasthenia gravis often requires ongoing treatment and monitoring. The need to reduce relapses and maintain daily function supports continued use of medicines and specialist care.

Market Challenges

  • High Cost of Advanced Biologics: Targeted therapies can carry substantial treatment costs, particularly for long-term use. Reimbursement restrictions and limited healthcare budgets may affect patient access.

  • Variable Patient Response: Treatment outcomes differ according to disease severity, antibody status, and individual response. Clinicians may need to adjust treatment plans, which can complicate care.

  • Limited Specialist Access: Diagnosis and treatment often require neurologists and specialized centers. Shortages of trained professionals and uneven access to advanced care can delay treatment in some regions.

Market Opportunities

  • New Targeted Treatments for Wider Patient Groups: Pharmaceutical developers can pursue therapies that address different antibody profiles and disease subtypes. Successful products can create revenue through specialist prescriptions, regional approvals, and partnerships with neurology centers.

  • Convenient Treatment Formats: Patients and healthcare providers may benefit from therapies with simpler administration schedules or at-home delivery options. Drug manufacturers can develop commercial opportunities through subcutaneous formulations, patient-support services, and treatment access programs.

Segment Analysis

By type, ocular myasthenia gravis led the market with a 54.3% share in 2025. Its position reflects the prevalence of eye-related symptoms, which can include drooping eyelids and double vision.

By treatment, autologous hematopoietic stem cell transplantation (HSCT) is expected to grow at a CAGR of 8.6% during the forecast period. Its use in selected patients with severe or treatment-resistant disease supports interest in specialized immune-reset approaches, although it remains a limited and highly specialized option.

By end user, hospitals held a 56.7% share in 2025. Their access to neurologists, diagnostic facilities, infusion services, and emergency care supports their role in the management of the condition.

Regional Analysis

North America held the largest market share in 2025, supported by access to advanced biologic therapies, specialist neurological care, and established reimbursement systems. The region also has a strong clinical research base for autoimmune and neuromuscular disorders.

Asia Pacific is expected to grow at a CAGR of 9.2%, supported by improvements in healthcare infrastructure, greater awareness of rare neurological disorders, and wider access to advanced therapies. Europe remains an established market due to specialist care networks and pharmaceutical research, while Latin America and the Middle East and Africa offer opportunities as diagnosis and treatment access improve.

Competitive Landscape

The competitive landscape includes pharmaceutical companies that develop conventional medicines, immunotherapies, and targeted biologics for autoimmune disorders. Companies compete through clinical efficacy, safety profiles, treatment convenience, regulatory approvals, and access programs. Key participants identified in the report include Valeant Pharmaceuticals International, Novartis Pharmaceuticals Corporation, Apotex Corporation, Teva Pharmaceutical Industries, and RPG Life Sciences.

Recent Developments

  • May 2026: Argenx received U.S. FDA approval to expand the indications for VYVGART and VYVGART Hytrulo to include adults with generalized myasthenia gravis across all serotypes, including anti-AChR, anti-MuSK, anti-LRP4, and triple-seronegative patients.

  • June 2026: TG Therapeutics reported positive top-line Phase 1 data for subcutaneous BRIUMVI in patients with myasthenia gravis and initiated a Phase 2 study to evaluate its use as maintenance therapy following efgartigimod treatment.

  • September 2026: Vor Bio completed enrollment in its global Phase 3 UPSTREAM MG trial of telitacicept for generalized myasthenia gravis. The company also outlined plans for a separate Phase 3 study in ocular myasthenia gravis.

Click to Read the Complete Insights & Report: https://straitsresearch.com/report/myasthenia-gravis-treatment-market

Explore the full Myasthenia Gravis Treatment Market report for detailed market estimates, segment-level analysis, regional forecasts, competitive insights, and strategic developments.

Future Outlook

The market is expected to benefit from continued development of targeted immunotherapies and broader treatment eligibility. New biologics, alternative administration formats, and clinical research into different disease subtypes may expand the available treatment pool. Better diagnosis and wider access to specialist neurological services are also likely to support long-term market development.

About Straits Research

Straits Research is a market intelligence and consulting firm that provides industry insights, market forecasts, and strategic research across a broad range of sectors. The company helps organizations understand market trends, assess competitive environments, and identify opportunities for business growth.


savi ssd ssd

7 Blog Mensajes

Comentarios

¡Instala Camlive!

Instala la app para obtener la mejor experiencia, notificaciones instantáneas y mejor rendimiento.